Table 3 Result of subsequent autologous stem cell transplantation
Cyclophosphamide (n = 57) | Etoposide (n = 56) | P value | |
|---|---|---|---|
Conditioning regimen, n (%) | < 0.001 | ||
High-dose melphalan | 48 (84.2) | 9 (16.1) | |
Melphalan with another agent | 9 (15.8) | 27 (48.2) | |
Busulfan-Thiotepa | 0 (0.0) | 20 (35.7) | |
Median infused CD34+ cells (× 106 CD34+/kg) | 5.71 (1.85 ~ 12.60) | 16.15 (7.10 ~ 39.00) | < 0.001 |
Post PBSC infusion hospitalization duration, days (range) | 15 (13~65) | 14 (12~54) | 0.005 |
Time to neutrophil engraftment (> 0.5 × 109/L), days | 11 (8 ~ 17) | 10 (8 ~ 15) | 0.292 |
Time to platelet engraftment (> 20 × 109/L), days | 9 (6 ~ 32) | 12 (7 ~ 13) | 0.055 |
Median number of platelet transfusions support during transplantation (range) | 4 (1~12) | 2 (0~8) | < 0.001 |
Pre-engraftment complications, n (%) | |||
Neutropenic fever | 41 (73.2) | 36 (67.9) | 0.674 |
Hepatic veno-occlusive disease | 0 (0.0) | 0 (0.0) | |
Hemorrhagic cystitis | 0 (0.0) | 0 (0.0) | |
Engraftment syndrome | 6 (11.1) | 7 (12.5) | 1.000 |
Early graft failure | 0 (0.0) | 0 (0.0) | |
Treatment-related mortality | 1 (1.8) | 2 (3.6) | 0.618 |